Tuesday, 22 August 2017

Dr Reddy`s Lab`s arm out licenses DFD-06 to Encore

Dr Reddy’s Laboratories Ltd has said that its wholly-owned subsidiary Promius Pharma has out-licensed the future development, manufacturing, and commercialisation rights of DFD-06, a topical high potency steroid, to Encore Dermatology Inc. The drug is intended to be used for the treatment of moderate to severe plaque psoriasis.
Under the terms of the agreement, Encore will be responsible for the commercialisation of DFD-06 in the US. Promius Pharma is eligible to receive certain pre- and post-commercialisation milestone payments of up to $32.5 million, followed by fixed royalty payments on net sales.
Meanwhile, shares of the company were trading at Rs 1956.65 apiece, up 1.22 per cent from the previous close at 11:14 hours on BSE.

BUY DRREDDY'S FUTURE ABOVE 1980 TG 2020, 2070 SL 1950,

http://tradenivesh.com/


BUY APOLLO HOSPITAL FUTURE ABOVE 1080 TG 1110, 1150 SL 1060,

For more information visit our website :www.tradenivesh.com

No comments:

Post a Comment

 
 
Blogger Templates